============================================================
IRIS GATE EVO — PROTOCOL PACKAGE
============================================================

Session: evo_20260210_231236_pharmacology
Date: 2026-02-10
Protocol: evo-1.0

QUESTION:
  What mechanisms explain why low-dose lithium is neuroprotective while therapeutic-dose lithium causes nephrotoxicity, and what molecular targets determine the dose-dependent switch between cytoprotection and organ toxicity?

CONVERGENCE:
  S2 rounds: 0
  Early stopped: False
  Final Jaccard: 0.0
  Final TYPE 0/1: 0.0
  S3 gate: PASSED

VERIFICATION:
  TYPE 2 claims checked: 4
  Promoted to TYPE 1: 0
  Novel (no literature): 2
  Contradicted: 0

LAB GATE:
  Result: PASSED
  Claims passed: 12/19

HYPOTHESES (ranked by testability):
  H1. IF renal collecting duct cells express functional ENaC, THEN intracellular [Li⁺] will be 2.5–4.0× extracellular [Li⁺] at
     Testability: 9.0/10
     Effect size: 1.172 (Cohen's d)
     Power: 1.0

  H2. IF renal cells are exposed to [Li⁺] >2 mM (mimicking renal intracellular levels), THEN AQP2 apical membrane insertion wi
     Testability: 8.0/10
     Effect size: 1.0586 (Cohen's d)
     Power: 1.0

  H3. IF primary cortical neurons are exposed to 0.3 mM Li⁺, THEN GSK-3β activity decreases 15–25%, Nrf2 nuclear translocation
     Testability: 8.0/10
     Effect size: 1.0642 (Cohen's d)
     Power: 1.0

  H4. IF collecting duct cells experience >50% GSK-3β inhibition (via 3 mM Li⁺), THEN β-catenin-dependent transcription (TOPFl
     Testability: 7.0/10
     Effect size: 0.8509 (Cohen's d)
     Power: 1.0

BUDGET:
  Total LLM calls: 11
  Target range: 92-142 calls

============================================================
Five mirrors. One truth. This is what converged.
============================================================